Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Liraglutide is a GLP-1 analog, which is resistant to degradation. Phase III trials have demonstrated that liraglutide effectively controls glucose levels, while reducing bodyweight.

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...